PetIQ Expands Its Portfolio by Acquiring MYOS and Fortetropin® for Enhanced Pet Muscle Health

In a strategic move to strengthen its foothold in the pet wellness industry, PetIQ, Inc., a prominent player in pet health, has officially finalized the acquisition of MYOS Corp. This acquisition is significant as it includes MYOS's clinically-tested muscle health products, particularly those featuring Fortetropin®, designed to support muscle preservation, injury recovery, and healthy aging in pets.

Strengthening Market Position

PetIQ, a product of Bansk Group, announced this acquisition on July 29, 2026. While financial details of the transaction remain undisclosed, the integration of MYOS’s muscle health solutions aligns perfectly with PetIQ’s mission to provide comprehensive wellness products for pets. This acquisition not only adds a technically advanced product range to PetIQ’s offerings but also enhances its reputation as a leading platform for pet health and wellness.

The products formed around Fortetropin®, a proprietary and patented compound, have been meticulously designed to support muscle growth and preservation. This bioactive ingredient functions by regulating myostatin, a protein that naturally inhibits muscle mass development in the body. Studies suggest that Fortetropin® improves muscle growth, enhances mobility, and mitigates muscle loss associated with aging or physical stress.

Meeting Demand for Preventive Solutions

CEO of PetIQ, Camillo Pane, noted the growing desire from pet owners for products that maintain their pets’ health, emphasizing the importance of preventive measures rather than reactive solutions. With MYOS's expertise developed over more than a decade of collaboration with veterinarians, PetIQ anticipates entering the lucrative muscle health market. Their aim is to meet the increasing consumer demand for products that enhance mobility and overall quality of life for pets, reinforcing PetIQ’s commitment to pet wellness.

MYOS Chief Executive Officer, Joe Mannello, expressed enthusiasm about the partnership, stating,